<div id="readability-page-1"><div> By Megan Cheah <pre></pre> Wuxi AppTec plans to raise around $1 billion by issuing U.S. dollar-settled zero coupon convertible bonds, as it seeks to boost its capacity and capabilities. The Shanghai-based company, which provides drug research, development and manufacturing services, plans to issue the bonds with a principal amount of 6.78 billion yuan, equivalent to $999 million, Wuxi AppTec said Friday. The bonds can be converted to Hong Kong-listed shares at an initial conversion price of 153 Hong Kong dollars per share, or $19.54, subject to adjustments and conditions, said the company, which is listed in both Shanghai and Hong Kong. The conversion price is a premium of around 18% over Wuxi AppTec's Thursday closing price of HK$130.10, the company said. Assuming full conversion of all the bonds at this price, the converted shares will represent around 9.1% of Wuxi's enlarged H-share capital and around 1.7% of its total issued share capital. Wuxi intends to use the net proceeds of around $1.02 billion for global capacity and capability expansion, and general corporate purposes. Morgan Stanley, Citigroup and Goldman Sachs are the banks advising Wuxi on its bond issuance. Wuxi AppTec's shares in Hong Kong closed 5.2% lower at HK$130.10 on Thursday, but are about 32% higher year to date. <pre></pre> Write to Megan Cheah at megan.cheah@wsj.com <pre></pre> (END) Dow Jones Newswires May 14, 2026 20:41 ET (00:41 GMT)Copyright (c) 2026 Dow Jones &amp; Company, Inc.</div></div>

02359

159892

512010

Wuxi AppTec plans to raise approximately $1 billion through U.S. dollar-settled zero coupon convertible bonds to enhance its capacity and capabilities. The bonds, convertible to shares at an initial price of HK$153, represent about 9.1% of the enlarged H-share capital. The proceeds will be used for global expansion and corporate purposes. Morgan Stanley, Citigroup, and Goldman Sachs are advising on the issuance.

MorningStar

WUXI APPTEC

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

E Fund CSI 300 Health Care ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

China Universal CNI HK Connect Innovative Drugs Industry ETF

E Fund CSI Biotechnology Theme ETF

ChinaAMC CSI Biotechnology Theme ETF

Hwabao WP CSI Pharmaceuticals ETF

Minsheng Royal CSI Biotechnology Theme ETF

Guotai CSI Bio-medicine ETF

Huatai-PB Hang Seng Innovative Drugs Industry ETF(QDII)

WuXi AppTec

Morgan Stanley

Citigroup

Goldman Sachs

MORGAN STANLEY DEP SHS EA REP 1/1000 SHS NON CUM PFD O

MORGAN STANLEY DEP SHS REPSTG 1/1000TH PFD SER Q

MORGAN STANLEY DEP SHS REPS 1/1000 7.125% PFD E

MORGAN STANLEY NON-CUM DEP SH REP 1/1000 PFD SER I

MORGAN STANLEY 4.875 DEP SHS REP 1/1000 NCUM PFD SR L

MORGAN STANLEY 6.5%DEP SHS REPSTG 1/1000 NON CUM SER P

MORGAN STANLEY DEP SHS REPS 1/1000 PFD SER 'A'

MORGAN STANLEY DEP SHS REPR 1/1000TH INT PFD SER 'F' FX

MORGAN STANLEY DEP SHS REP 1/1000 NON-CUM PFD STK SER K

CITIGROUP INC 6.250 NON CUM SER II PFD WI

GS Hldg R

Wuxi AppTec to Raise Around $1 Billion Through Zero Coupon Convertible Bonds